Protalix BioTherapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2 University Plz Ste 100, Hackensack, Ne...Phone Number
+972 49028100Website
www.protalix.comRevenue
$76.4 MillionStock Symbol
PLXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Protalix BioTherapeutics
Founded in 1993 Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company is headquartered in Carmiel, Isreal.Explore more
Protalix BioTherapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Protalix BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Protalix BioTherapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Protalix BioTherapeutics
Check if Protalix BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Protalix BioTherapeutics recently announced quarterly report
Protalix BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Protalix BioTherapeutics has new funding data
Click to see if Protalix BioTherapeutics had a recent Job posting/layoffs
Check out if Protalix BioTherapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Protalix BioTherapeutics
Compare insights from companies similar to Protalix BioTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$19.3M
51-200
Private
-
2008
TS
Trushant ShahNeo Wealth & Asset Management Vice President, Corporate Strategy
$17.3M
51-200
Private
$71M
2014
GR
Guy RachmuthSenior Vice President, Global Head of Strategic BD and Partnerships. Chief Business Officer
Company Profile Activity
Activity Insights
Protalix BioTherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Protalix BioTherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Protalix BioTherapeutics.
Protalix BioTherapeutics financials insights
Gather financial insights about Protalix BioTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$43.7M
2021
Share Placement
$35M
Protalix BioTherapeutics Tech Stack
A closer look at the technologies used by Protalix BioTherapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Pharmaceuticals, Finance
Person-Based
Person-Based
Earnings, Finance
Earnings
Earnings, Forecasting, Finance
Protalix BioTherapeutics News & Media
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
Protalix BioTherapeutics (AMEX:PLX) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1762414&tp_key=330c698581 Summary Protalix BioTherapeutics reported a $25 million milestone payment from Chiesi due to European Commission aProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25 million milestone received from Chiesi PRX–115 Phase 2 study continues to advance as...Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics...Protalix CFO updates Form 3 share and option holdings | PLX Insider Trading - Stock Titan
Protalix BioTherapeutics CFO Gilad Mamlok reports 3,631 common shares and stock options on 597,990 shares at $1.45, vesting quarterly with potential acceleration on a corporate transaction or change in control.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Protalix BioTherapeutics
Sign Up For FreeTo access detailed company insights
Founded in 1993 Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. The company is headquartered in Carmiel, Isreal.... Read More
